Association of HDL and LDL levels with osteoporosis in rheumatoid arthritis: a retrospective cohort study.
Correlation
High-density lipoprotein
Low-density lipoprotein
Osteoporosis
Rheumatoid arthritis
Journal
European journal of medical research
ISSN: 2047-783X
Titre abrégé: Eur J Med Res
Pays: England
ID NLM: 9517857
Informations de publication
Date de publication:
29 Aug 2024
29 Aug 2024
Historique:
received:
16
02
2024
accepted:
05
08
2024
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
29
8
2024
Statut:
epublish
Résumé
A correlation exists between lipids and osteoporosis (OP), as well as between lipids and rheumatoid arthritis (RA). However, lipids, the relationship between RA and OP is still unclear. This study mainly investigates the relationship between lipid levels and OP risk in RA patients. Retrospective collection of RA patient data from July 2017 to May 2022, encompassing baseline demographics, treatment regimens, laboratory results, and bone mineral density (BMD) measurements. Analyses, stratified by BMD subgroups, were conducted using propensity score matching (PSM) based on age, sex, and baseline duration, and binary logistic regression to examine the interplay between lipoprotein levels and other risk factors. The relationship between continuous variables and OP risk was assessed using restricted cubic spline (RCS), followed by a reanalysis of the correlation between varying lipoprotein levels and different factors, segmented according to RCS-determined cutoffs. The study included 2673 RA patients. Binary logistic regression revealed significant associations between high-density lipoprotein (HDL), low-density lipoprotein (LDL), and RA-OP (p < 0.01). Specifically, HDL emerged as a protective factor against OP (OR = 0.40, 95% CI 0.250-0.629; p < 0.001), whereas LDL was identified as a risk factor (OR = 1.56, 95% CI 1.290-1.890; p < 0.001). Furthermore, HDL (RCS cutoff point 1.28 mmol/L) showed a negative, linear correlation with RA-related OP, while LDL (RCS cutoff point 2.63 mmol/L) demonstrated a positive, linear correlation. The levels of HDL and LDL may be indicators of OP occurrence in RA patients.
Identifiants
pubmed: 39210479
doi: 10.1186/s40001-024-02013-0
pii: 10.1186/s40001-024-02013-0
doi:
Substances chimiques
Lipoproteins, LDL
0
Lipoproteins, HDL
0
Cholesterol, HDL
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
439Subventions
Organisme : Key Laboratory of Integrated Traditional Chinese and Western Medicine in the Prevention and Treatment of Disease Transformation in Higher Education Institutions in Guizhou Province
ID : Qian Jiao Ji [2023] No. 017
Organisme : Guizhou University of Traditional Chinese Medicine National and Provincial Science and Technology Innovation Talent Team Cultivation Project
ID : Guizhou University of Traditional Chinese Medicine TD NO.[2022]004
Organisme : Program of the National Natural Science Foundation of China
ID : 82160917
Informations de copyright
© 2024. The Author(s).
Références
Farquhar H, Beckert L, Edwards A, et al. Rheumatoid interstitial lung disease in canterbury new zealand: prevalence, risk factors and long-term outcomes-protocol for a population-based retrospective study. BMJ Open. 2022;12:e50934.
doi: 10.1136/bmjopen-2021-050934
Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73:1316–22.
doi: 10.1136/annrheumdis-2013-204627
pubmed: 24550173
Zahid PM, Samreen S, Khan ZA, et al. Factors associated with low bone mineral density in postmenopausal women with rheumatoid arthritis. J Pak Med Assoc. 2022;72:891–5.
doi: 10.47391/JPMA.3058
pubmed: 35713051
Moshayedi S, Tasorian B, Almasi-Hashiani A. The prevalence of osteoporosis in rheumatoid arthritis patient: a systematic review and meta-analysis. Sci Rep. 2022;12:15844.
doi: 10.1038/s41598-022-20016-x
pubmed: 36151246
pmcid: 9508181
Stemmler F, Simon D, Liphardt AM, et al. Biomechanical properties of bone are impaired in patients with acpa-positive rheumatoid arthritis and associated with the occurrence of fractures. Ann Rheum Dis. 2018;77:973–80.
doi: 10.1136/annrheumdis-2017-212404
pubmed: 29475856
Takahashi K, Setoguchi T, Tawaratsumida H, et al. Risk of low bone mineral density in patients with rheumatoid arthritis treated with biologics. Bmc Musculoskelet Disord. 2015;16:269.
doi: 10.1186/s12891-015-0732-x
pubmed: 26420629
pmcid: 4589107
Huang H, Wang Y, Xie W, et al. Impact of treat-to-target therapy on bone mineral density loss in patients with rheumatoid arthritis: a prospective cohort study. Front Endocrinol (Lausanne). 2022;13:867610.
doi: 10.3389/fendo.2022.867610
pubmed: 35655798
Cheng TT, Lai HM, Yu SF, et al. The impact of low-dose glucocorticoids on disease activity, bone mineral density, fragility fractures, and 10-year probability of fractures in patients with rheumatoid arthritis. J Investig Med. 2018;66:1004–7.
doi: 10.1136/jim-2018-000723
pubmed: 29891493
pmcid: 6073913
Maradit-Kremers H, Nicola PJ, Crowson CS, et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2005;52:722–32.
doi: 10.1002/art.20878
pubmed: 15751097
Anagnostis P, Florentin M, Livadas S, et al. Bone health in patients with dyslipidemias: an underestimated aspect. Int J Mol Sci. 2022;23:1639.
doi: 10.3390/ijms23031639
pubmed: 35163560
pmcid: 8835770
Tintut Y, Demer LL. Effects of bioactive lipids and lipoproteins on bone. Trends Endocrinol Metab. 2014;25:53–9.
doi: 10.1016/j.tem.2013.10.001
pubmed: 24183940
Karadeniz F, Oh JH, Jo HJ, et al. Myricetin 3-o-beta-d-galactopyranoside exhibits potential anti-osteoporotic properties in human bone marrow-derived mesenchymal stromal cells via stimulation of osteoblastogenesis and suppression of adipogenesis. Cells. 2021;10:2690.
doi: 10.3390/cells10102690
pubmed: 34685670
pmcid: 8534343
McGrath CM, Young SP. Lipid and metabolic changes in rheumatoid arthritis. Curr Rheumatol Rep. 2015;17:57.
doi: 10.1007/s11926-015-0534-z
pubmed: 26210510
Muruganandan S, Sinal CJ. The impact of bone marrow adipocytes on osteoblast and osteoclast differentiation. IUBMB Life. 2014;66:147–55.
doi: 10.1002/iub.1254
pubmed: 24638917
Wang T, He C, Yu X. Pro-inflammatory cytokines: new potential therapeutic targets for obesity-related bone disorders. Curr Drug Targets. 2017;18:1664–75.
doi: 10.2174/1389450118666170104153512
pubmed: 28056748
Musso G, Paschetta E, Gambino R, et al. Interactions among bone, liver, and adipose tissue predisposing to diabesity and fatty liver. Trends Mol Med. 2013;19:522–35.
doi: 10.1016/j.molmed.2013.05.006
pubmed: 23816817
Ko SH, Jung Y. Energy metabolism changes and dysregulated lipid metabolism in postmenopausal women. Nutrients. 2021;13:4556.
doi: 10.3390/nu13124556
pubmed: 34960109
pmcid: 8704126
Wei X, Zhang Y, Sun C, et al. Elucidating the relationship between dyslipidemia and osteoporosis: a multicenter, prospective cohort study protocol. Front Cardiovasc Med. 2022;9:901786.
doi: 10.3389/fcvm.2022.901786
pubmed: 36186975
pmcid: 9515467
Marchand GB, Carreau AM, Weisnagel SJ, et al. Increased body fat mass explains the positive association between circulating estradiol and insulin resistance in postmenopausal women. Am J Physiol Endocrinol Metab. 2018;314:E448–56.
doi: 10.1152/ajpendo.00293.2017
pubmed: 29208612
Ersoy GS, Simsek EE, Vatansever D, et al. Lipid profile and plasma atherogenic index in postmenopausal osteoporosis. North Clin Istanb. 2017;4:237–41.
pubmed: 29270572
pmcid: 5724918
Bijelic R, Balaban J, Milicevic S. Correlation of the lipid profile, bmi and bone mineral density in postmenopausal women. Mater Sociomed. 2016;28:412–5.
doi: 10.5455/msm.2016.28.412-415
pubmed: 28144189
pmcid: 5239653
Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an american college of rheumatology/european league against rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569–81.
doi: 10.1002/art.27584
pubmed: 20872595
Prevoo ML, van Hof TM, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44–8.
doi: 10.1002/art.1780380107
pubmed: 7818570
Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology. 2003;42:244–57.
doi: 10.1093/rheumatology/keg072
pubmed: 12595618
Aletaha D, Smolen J. The simplified disease activity index (sdai) and the clinical disease activity index (cdai): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol. 2005;23:S100–8.
pubmed: 16273793
Jazbar J, Locatelli I, Kos M. The association between medication or alcohol use and the incidence of frailty: a retrospective cohort study. Bmc Geriatr. 2021;21:25.
doi: 10.1186/s12877-020-01969-y
pubmed: 33413145
pmcid: 7791729
Cleeman JI. Executive summary of the third report of the national cholesterol education program (ncep) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel iii). Jama. 2001;285:2486–97.
doi: 10.1001/jama.285.19.2486
Zeng T, Tan L, Yu J, et al. High density lipoprotein in rheumatoid arthritis: emerging role in predicting inflammation level and osteoporosis occurrence. Scand J Clin Lab Invest. 2020;80:375–80.
doi: 10.1080/00365513.2020.1747109
pubmed: 32279574
Llorente I, Merino L, Ortiz AM, et al. Anti-citrullinated protein antibodies are associated with decreased bone mineral density: baseline data from a register of early arthritis patients. Rheumatol Int. 2017;37:799–806.
doi: 10.1007/s00296-017-3674-9
pubmed: 28243799
pmcid: 5397447
Humphrey MB, Russell L, Danila MI, et al. 2022 american college of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol. 2023;75:2088–102.
doi: 10.1002/art.42646
pubmed: 37845798
Kim JY, Lee EY, Park JK, et al. Patients with rheumatoid arthritis show altered lipoprotein profiles with dysfunctional high-density lipoproteins that can exacerbate inflammatory and atherogenic process. PLoS ONE. 2016;11:e164564.
Han R, Wu Y, Han Y, et al. Engineered plant extracellular vesicles for autoimmune diseases therapy. Nano Res. 2023. https://doi.org/10.1007/s12274-023-6112-1 .
doi: 10.1007/s12274-023-6112-1
pubmed: 36465522
Zeng ZL, Xie H. Mesenchymal stem cell-derived extracellular vesicles: a possible therapeutic strategy for orthopaedic diseases: a narrative review. Biomater Transl. 2022;3:175–87.
pubmed: 36654775
pmcid: 9840092
Liu H, Li R, Liu T, et al. Immunomodulatory effects of mesenchymal stem cells and mesenchymal stem cell-derived extracellular vesicles in rheumatoid arthritis. Front Immunol. 2020;11:1912.
doi: 10.3389/fimmu.2020.01912
pubmed: 32973792
pmcid: 7468450
Liu C, Chen X, Zhi X, et al. Structure-based development of an osteoprotegerin-like glycopeptide that blocks rankl/rank interactions and reduces ovariectomy-induced bone loss in mice. Eur J Med Chem. 2018;145:661–72.
doi: 10.1016/j.ejmech.2018.01.022
pubmed: 29348072
de Araujo JR, Souza TO, de Moura LM, et al. Atorvastatin decreases bone loss, inflammation and oxidative stress in experimental periodontitis. PLoS ONE. 2013;8:e75322.
doi: 10.1371/journal.pone.0075322
pubmed: 24130702
pmcid: 3794930
Li B, Wang Y, Gong S, et al. Puerarin improves ovx-induced osteoporosis by regulating phospholipid metabolism and biosynthesis of unsaturated fatty acids based on serum metabolomics. Phytomedicine. 2022;102:154198.
doi: 10.1016/j.phymed.2022.154198
pubmed: 35636175
Maghbooli Z, Khorrami-Nezhad L, Adabi E, et al. Negative correlation of high-density lipoprotein-cholesterol and bone mineral density in postmenopausal iranian women with vitamin d deficiency. Menopause. 2018;25:458–64.
doi: 10.1097/GME.0000000000001082
pubmed: 29557847
Wang B, Wang H, Li Y, et al. Lipid metabolism within the bone micro-environment is closely associated with bone metabolism in physiological and pathophysiological stages. Lipids Health Dis. 2022;21:5.
doi: 10.1186/s12944-021-01615-5
pubmed: 34996476
pmcid: 8742318
Li Z, Li D, Chen R, et al. Cell death regulation: a new way for natural products to treat osteoporosis. Pharmacol Res. 2023;187:106635.
doi: 10.1016/j.phrs.2022.106635
pubmed: 36581167
Haque UJ, Bathon JM, Giles JT. Association of vitamin d with cardiometabolic risk factors in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64:1497–504.
doi: 10.1002/acr.21715
pubmed: 22555877